Antimicrobial Agents Used in ESBL Patients
| Antimicrobial Agent | Frequency (%) |
|---|---|
| Ertapenem | 92 (76.0%) |
| Meropenem | 18 (14.9%) |
| Tigecycline | 6 (13.2%) |
| Ceftazidime | 5 (4.1%) |
| Total | 121 (100%) |
Diagnoses of Patients with ESBL Infection
| Diagnosis | Frequency (%) |
|---|---|
| UTI | 85 (70.2%) |
| Urosepsis | 18 (14.9%) |
| Osteomyelitis | 15 (12.4%) |
| Pneumonia | 2 (1.7%) |
| Liver abscess | 1 (0.8%) |
| Total | 121 (100%) |
Complications in Patients with ESBL Infections During Therapy
| Complication | ESBL | All | P Value |
|---|---|---|---|
| Complications | 19 (42.2%) | 45 | 0.41 |
| Persistent infection | 10 (52.6%) | 19 | 0.66 |
| Sepsis | 3 (33.3%) | 9 | 0.38 |
| Readmission | 31 (62.0%) | 50 | 0.67 |
| ER visits | 40 (60.6%) | 66 | 0.02 |
| Deaths | 5 (42.7%) | 12 | 0.66 |
ESBL Pathogens and Susceptibility
| Pathogen | Frequency (%) |
|---|---|
| Escherichia coli | 92 (76.0%) |
| Pan resistant (E.coli) | 3 (3.3%) |
| Klebsiella pneumoniae | 23 (19.0%) |
| Pan resistant (Klebsiella) | 4 (17.4%) |
| Serratia marcescens | 2 (1.7%) |
| Pseudomonas aeruginosa | 2 (1.7%) |
| Enterobacter cloacae | 1 (0.8%) |
| Morganella morganii | 1 (0.8%) |
| Total | 121 (100%) |
Patient Characteristics
| Variable | ESBL | All |
|---|---|---|
| Female | ESBL: 77 (63.6%) | All: 144 (56.9%) |
| Male | ESBL: 44 (36.4%) | All: 109 (43.1%) |
| Total | ESBL: 121 (47.8%) | All: 253 (100%) |
| Age (Mean ± SD) | ESBL: 74.5 ± 13.8 | All: 72.2 ± 15.5 |
| Registered to other HHC programs | ESBL: 67 (55.4%) | All: 129 (51.0%) |
| Deaths | ESBL: 5 (4.1%) | All: 12 (4.7%) |
Risk Factors in Patients with ESBL Infections
| Risk Factor | ESBL | All | P Value |
|---|---|---|---|
| Female gender | 77 (53.5%) | 144 | 0.04 |
| UTI history | 115 (55.6%) | 207 | 0.00 |
| ESBL history | 98 (73.7%) | 133 | 0.00 |
| DM | 89 (49.2%) | 181 | 0.48 |
| CKD | 49 (54.4%) | 90 | 0.12 |
| Cognitive impairment | 41 (57.0%) | 72 | 0.07 |
| BPH* | 21 (60.0%) | 35 | 0.00 |
| Catheter* | 10 (50.0%) | 20 | 0.33 |